drugset
drugset / Trial / NCT05624944

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

NCT05624944 ↗

Phase 1 Completed 84 enrolled Taisho Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label pharmacokinetic study of TS-142 in patients with hepatic impairment

Timeline

Start
2022-12-26
Primary completion
2023-12-05
Completion
2023-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-142 Small molecule 5 mg —

Indications

No indication recorded.